ArticleFrontiers in immunology2018
Quantification of HLA-DM-Dependent Major Histocompatibility Complex of Class II Immunopeptidomes by the Peptide Landscape Antigenic Epitope Alignment Utility.
Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 46 citations in OpenAlex.
- A red blood cell-based antigen delivery system to facilitate T cell epitope presentation to promote peripheral tolerance to ADAMTS13 in immune-mediated thrombotic thrombocytopenic purpura.Research and practice in thrombosis and haemostasis · 2026Article
- Cut or bind? Antigen-specific processing mechanisms define CD4Genome medicine · 2025Article
- Development of therapeutic cancer vaccines based on cancer immunity cycle.Frontiers of medicine · 2025Review
- FASTMAP-a flexible and scalable immunopeptidomics pipeline for HLA- and antigen-specific T-cell epitope mapping based on artificial antigen-presenting cells.Frontiers in immunology · 2024Article
- MHC Class II Presentation in Autoimmunity.Cells · 2023Review
- CD4+ T Cell Epitope Identification from Complex Parasite Antigen Mixtures.Methods in molecular biology (Clifton, N.J.) · 2023Article
- The Autophagy Receptor TAX1BP1 (T6BP) improves antigen presentation by MHC-II molecules.EMBO reports · 2022Article
- Natural variation of ncHLAII molecules: challenges and perspectives.Cellular & molecular immunology · 2022Article
- Therapeutic Vaccines Targeting Neoantigens to Induce T-Cell Immunity against Cancers.Pharmaceutics · 2022Review
- Tuning DO:DM Ratios Modulates MHC Class II Immunopeptidomes.Molecular & cellular proteomics : MCP · 2022Article
- Molecular Determinants Regulating the Plasticity of the MHC Class II Immunopeptidome.Frontiers in immunology · 2022Review
- 1,2,3, MHC: a review of mass-spectrometry-based immunopeptidomics methods for relative and absolute quantification of pMHCs.Immuno-oncology technology · 2021Review
- HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy.Journal for immunotherapy of cancer · 2021Article
- Distinguishing Signal From Noise in Immunopeptidome Studies of Limiting-Abundance Biological Samples: Peptides Presented by I-AFrontiers in immunology · 2021Article
- Automated Ligand Purification Platform Accelerates Immunopeptidome Analysis by Mass Spectrometry.Journal of proteome research · 2021Article
- An Integrated Genomic, Proteomic, and Immunopeptidomic Approach to Discover Treatment-Induced Neoantigens.Frontiers in immunology · 2021Article
- Dynamic palmitoylation events following T-cell receptor signaling.Communications biology · 2020Article
- Distinct editing functions of natural HLA-DM allotypes impact antigen presentation and CD4Cellular & molecular immunology · 2020Article
- CD4NPJ vaccines · 2020Article
- Tumor neoantigens: from basic research to clinical applications.Journal of hematology & oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The major histocompatibility complex of class II (MHCII) immunopeptidome represents the repertoire of antigenic peptides with the potential to activate CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.